Prostate Cancer Prevention

  • Suzanne Stratton
  • Frederick Ahmann


Prostate Cancer Androgen Receptor Prostate Cancer Cell Radical Prostatectomy Prostate Cancer Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abate-Shen, C. and M.M. Shen (2000). "Molecular genetics of prostate cancer." Genes Dev 14(19): 2410–2434.CrossRefPubMedGoogle Scholar
  2. Agarwal, R. (2000). "Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents." Biochem Pharmacol 60(8): 1051–1059.CrossRefPubMedGoogle Scholar
  3. Alsikafi, N.F., C.B. Brendler, et al. (2001). "High-grade prostatic intraepithelial neoplasia with adjacent atypia is associated with a higher incidence of cancer on subsequent needle biopsy than high-grade prostatic intraepithelial neoplasia alone." Urology 57(2): 296–300.CrossRefPubMedGoogle Scholar
  4. Andriole, G.L. and W.J. Catalona (1993). "Using PSA to screen for prostate cancer. The Washington University experience." Urol Clin North Am 20(4): 647–651.PubMedGoogle Scholar
  5. Apakama, I., M.C. Robinson, et al. (1996). "bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer." Br J Cancer 74(8): 1258–1262.PubMedGoogle Scholar
  6. Aspden, W.J., R.J. Rodgers, et al. (1998). "Changes in testicular steroidogenic acute regulatory (STAR) protein, steroidogenic enzymes and testicular morphology associated with increased testosterone secretion in bulls receiving the luteinizing hormone releasing hormone agonist deslorelin." Domest Anim Endocrinol 15(4): 227–238.CrossRefPubMedGoogle Scholar
  7. Baldwin, A.S., Jr. (1996). "The NF-kappa B and I kappa B proteins: new discoveries and insights." Annu Rev Immunol 14: 649–683.CrossRefPubMedGoogle Scholar
  8. Banerjee, A.G., J. Liu, et al. (2003). "Expression of biomarkers modulating prostate cancer angiogenesis: Differential expression of annexin II in prostate carcinomas from India and USA." Mol Cancer 2(1): 34.CrossRefPubMedGoogle Scholar
  9. Barqawi, A., I.M. Thompson, et al. (2004). "Prostate cancer chemoprevention: an overview of United States trials." J Urol 171(2 Pt 2): S5–8; discussion S9.CrossRefPubMedGoogle Scholar
  10. Bartels, P.H., R. Montironi, et al. (1998). "Nuclear chromatin texture in prostatic lesions. I. PIN and adenocarcinoma." Anal Quant Cytol Histol 20(5): 389–396.PubMedGoogle Scholar
  11. Bartels, P.H., R. Montironi, et al. (1998). "Nuclear chromatin texture in prostatic lesions. II. PIN and malignancy associated changes." Anal Quant Cytol Histol 20(5): 397–406.PubMedGoogle Scholar
  12. Beilin, J., L. Harewood, et al. (2001). "A case-control study of the androgen receptor gene CAG repeat polymorphism in Australian prostate carcinoma subjects." Cancer 92(4): 941–949.CrossRefPubMedGoogle Scholar
  13. Bishop, M.C. (2000). "Trends in prostate cancer mortality in England, Wales, and the USA." Lancet Oncol 1(1): 14.CrossRefGoogle Scholar
  14. Borboroglu, P.G., S.W. Comer, et al. (2000). "Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies." J Urol 163(1): 158–162.CrossRefPubMedGoogle Scholar
  15. Bost, K.L. and M.J. Mason (1995). "Thapsigargin and cyclopiazonic acid initiate rapid and dramatic increases of IL-6 mRNA expression and IL-6 secretion in murine peritoneal macrophages." J Immunol 155(1): 285–296.PubMedGoogle Scholar
  16. Bostwick, D.G. (2000). "Prostatic intraepithelial neoplasia." Curr Urol Rep 1(1): 65–70.PubMedGoogle Scholar
  17. Bours, V., M. Bentires-Alj, et al. (2000). "Nuclear factor-kappa B, cancer, and apoptosis." Biochem Pharmacol 60(8): 1085–1089.CrossRefPubMedGoogle Scholar
  18. Burks, D.A. and R.H. Littleton (1992). "The epidemiology of prostate cancer in black men." Henry Ford Hosp Med J 40(1–2): 89–92.PubMedGoogle Scholar
  19. Cabeza-Arvelaiz, Y., J.L. Sepulveda, et al. (2001). "Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22." Oncogene 20(31): 4169–4179.CrossRefPubMedGoogle Scholar
  20. Carroll, P.R. (2003). "Trends in prostate cancer mortality among black men and white men in the United States. Chu KC, Tarone RE, Freeman HP, Center to Reduce Cancer Health Disparities, National Cancer Institute, Bethesda, MD. Cancer 2003;97:1507–1516." Urol Oncol 21(6): 483–484.Google Scholar
  21. Carty, S.E., C.M. Buresh, et al. (1991). "Decreased IL-6 secretion by fibroblasts following repeated doses of TNF alpha or IL-1 alpha: post-transcriptional gene regulation." J Surg Res 51(1): 24–32.CrossRefPubMedGoogle Scholar
  22. Cassidy, A. (2003). "Potential risks and benefits of phytoestrogen-rich diets." Int J Vitam Nutr Res 73(2): 120–126.PubMedGoogle Scholar
  23. Catalona, W.J., J.P. Richie, et al. (1994). "Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves." J Urol 152(6 Pt 1): 2031–2036.PubMedGoogle Scholar
  24. Chun, Y.J., M.Y. Kim, et al. (1999). "Resveratrol is a selective human cytochrome P450 1A1 inhibitor." Biochem Biophys Res Commun 262(1): 20–24.CrossRefPubMedGoogle Scholar
  25. Chung, T.D., J.J. Yu, et al. (1999). "Characterization of the role of IL-6 in the progression of prostate cancer." Prostate 38(3): 199–207.CrossRefPubMedGoogle Scholar
  26. Clark, L.C., G.F. Combs, Jr., et al. (1996). "Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group." JAMA 276(24): 1957–1963.CrossRefPubMedGoogle Scholar
  27. Clark, L.C. and E.T. Jacobs (1998). "Environmental selenium and cancer: risk or protection" Cancer Epidemiol Biomarkers Prev 7(10): 847–848; discussion 851–852.PubMedGoogle Scholar
  28. Clegg, L.X., F.P. Li, et al. (2002). "Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study." Arch Intern Med 162(17): 1985–1993.CrossRefPubMedGoogle Scholar
  29. Cronauer, M.V., W.A. Schulz, et al. (2003). "The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling (Review)." Int J Oncol 23(4): 1095–1102.PubMedGoogle Scholar
  30. Delmas, D., C. Rebe, et al. (2003). "Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells." J Biol Chem 278(42): 41482–41490.CrossRefPubMedGoogle Scholar
  31. Dessypris, A.G. (1975). "Testosterone sulphate, its biosynthesis, metabolism, measurement, functions and properties." J Steroid Biochem 6(8): 1287–1298.CrossRefPubMedGoogle Scholar
  32. Dhanalakshmi, S., P. Agarwal, et al. (2003). "Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin-and carboplatin-induced growth inhibition and apoptotic death." Int J Cancer 106(5): 699–705.CrossRefPubMedGoogle Scholar
  33. Djavan, B., A. Zlotta, et al. (2000). "Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men." J Urol 163(4): 1144–1148; discussion 1148–1149.CrossRefPubMedGoogle Scholar
  34. Duffield-Lillico, A.J., B.L. Dalkin, et al. (2003). "Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial." BJU Int 91(7): 608–612.CrossRefPubMedGoogle Scholar
  35. Durkan, G.C. and D.R. Greene (1999). "Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy?" BJU Int 83(1): 34–38.CrossRefGoogle Scholar
  36. Eastham, J.A., R.A. May, et al. (1998). "Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer." J Natl Cancer Inst 90(10): 756–760.CrossRefPubMedGoogle Scholar
  37. Ellis, W.J. and M.K. Brawer (1995). "Repeat prostate needle biopsy: who needs it?" J Urol 153(5): 1496–1498.CrossRefPubMedGoogle Scholar
  38. Erbersdobler, A., H. Fritz, et al. (2002). "Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone." Eur Urol 41(1): 40–46.CrossRefPubMedGoogle Scholar
  39. Etzioni, R., K.M. Berry, et al. (2002). "Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991–1998." Urology 59(2): 251–255.CrossRefPubMedGoogle Scholar
  40. Fleshner, N.E., M. O'Sullivan, et al. (1997). "Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate." J Urol 158(2): 505–508; discussion 508–509.CrossRefPubMedGoogle Scholar
  41. Fosslien, E. (2001). "Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis." Ann Clin Lab Sci 31(4): 325–348.PubMedGoogle Scholar
  42. Fowler, J.E., Jr., S.A. Bigler, et al. (2001). "Prospective study of correlations between biopsy-detected high grade prostatic intraepithelial neoplasia, serum prostate specific antigen concentration, and race." Cancer 91(7): 1291–1296.CrossRefPubMedGoogle Scholar
  43. Fowler, J.E., Jr., S.A. Bigler, et al. (2000). "Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer." J Urol 163(3): 813–818.CrossRefPubMedGoogle Scholar
  44. Gasparian, A.V., Y.J. Yao, et al. (2002). "Selenium compounds inhibit I kappa B kinase (IKK) and nuclear factor-kappa B (NF-kappa B) in prostate cancer cells." Mol Cancer Ther 1(12): 1079–1087.PubMedGoogle Scholar
  45. Gerber, G.S. (2000). "Saw palmetto for the treatment of men with lower urinary tract symptoms." J Urol 163(5): 1408–1412.CrossRefPubMedGoogle Scholar
  46. Gerber, G.S., D. Kuznetsov, et al. (2001). "Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms." Urology 58(6): 960–964; discussion 964–965.CrossRefPubMedGoogle Scholar
  47. Giovannucci, E. and E. Platz (2002). Nutritional and Environmental Epidemiology of Prostate Cancer. Prostate Cancer Principles and Practice, Lippincott Williams & Wilkins, 8th Edition: 117–139.Google Scholar
  48. Godbey, W.T. and A. Atala (2003). "Directed apoptosis in Cox-2-overexpressing cancer cells through expression-targeted gene delivery." Gene Ther 10(17): 1519–1527.CrossRefPubMedGoogle Scholar
  49. Goldmann, W.H., A.L. Sharma, et al. (2001). "Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells." Cell Biol Int 25(11): 1117–1124.CrossRefPubMedGoogle Scholar
  50. Gross, A., J.M. McDonnell, et al. (1999). "BCL-2 family members and the mitochondria in apoptosis." Genes Dev 13(15): 1899–1911.PubMedGoogle Scholar
  51. Guinan, P., N. Gilham, et al. (1981). "What is the best test to detect prostate cancer?" CA Cancer J Clin 31(3): 141–145.PubMedGoogle Scholar
  52. Henshall, S.M., D.I. Quinn, et al. (2001). "Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients." Clin Cancer Res 7(3): 544–550.PubMedGoogle Scholar
  53. Hilbert, D.M., M. Kopf, et al. (1995). "Interleukin 6 is essential for in vivo development of B lineage neoplasms." J Exp Med 182(1): 243–248.CrossRefPubMedGoogle Scholar
  54. Holund, B. (1980). "Latent prostatic cancer in a consecutive autopsy series." Scand J Urol Nephrol 14(1): 29–35.PubMedGoogle Scholar
  55. Hsing, A.W., Y.T. Gao, et al. (2000). "Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China." Cancer Res 60(18): 5111–5116.PubMedGoogle Scholar
  56. Hsu, A.L., T.T. Ching, et al. (2000). "The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2." J Biol Chem 275(15): 11397–11403.CrossRefPubMedGoogle Scholar
  57. Hzyek (1995). "Prostate Biopsy Rates." Curr Opinion in Urology 9(371).Google Scholar
  58. Iczkowski, K.A., C.G. Pantazis, et al. (2002). "Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma." Cancer 95(12): 2487–2493.CrossRefPubMedGoogle Scholar
  59. Imai, K., Y. Ichinose, et al. (1994). "Clinical significance of prostate specific antigen for early stage prostate cancer detection." Jpn J Clin Oncol 24(3): 160–165.PubMedGoogle Scholar
  60. Imai, M., H.Y. Hwang, et al. (2004). "The effect of dexamethasone on human mucin 1 expression and antibody-dependent complement sensitivity in a prostate cancer cell line in vitro and in vivo." Immunology 111(3): 291–297.CrossRefPubMedGoogle Scholar
  61. Irvine, R.A., M.C. Yu, et al. (1995). "The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer." Cancer Res 55(9): 1937–1940.PubMedGoogle Scholar
  62. Jang, M., L. Cai, et al. (1997). "Cancer chemopreventive activity of resveratrol, a natural product derived from grapes." Science 275(5297): 218–220.CrossRefPubMedGoogle Scholar
  63. Jemal, A., R.C. Tiwari, et al. (2004). "Cancer statistics, 2004." CA Cancer J Clin 54(1): 8–29.PubMedGoogle Scholar
  64. Jiang, C., Z. Wang, et al. (2001). "Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells." Cancer Res 61(7): 3062–3070.PubMedGoogle Scholar
  65. Jirik, F.R., T.J. Podor, et al. (1989). "Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells." J Immunol 142(1): 144–147.PubMedGoogle Scholar
  66. Johnson, A.J., X. Song, et al. (2001). "Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells." Adv Enzyme Regul 41: 221–235.CrossRefPubMedGoogle Scholar
  67. Johnson, M.I. and F.C. Hamdy (1998). "Apoptosis regulating genes in prostate cancer (review)." Oncol Rep 5(3): 553–557.PubMedGoogle Scholar
  68. Johnson, M.I., M.C. Robinson, et al. (1998). "Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation." Prostate 37(4): 223–229.CrossRefPubMedGoogle Scholar
  69. Kagan, J., J. Stein, et al. (1995). "Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes." Oncogene 11(10): 2121–2126.PubMedGoogle Scholar
  70. Kamijo, T., T. Sato, et al. (2001). "Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines." Int J Urol 8(7): S35–39.CrossRefPubMedGoogle Scholar
  71. Kamoi, K., P. Troncoso, et al. (2000). "Strategy for repeat biopsy in patients with high grade prostatic intraepithelial neoplasia." J Urol 163(3): 819–823.CrossRefPubMedGoogle Scholar
  72. Kapadia, G.J., M.A. Azuine, et al. (2002). "Inhibitory effect of herbal remedies on 12-O-tetra-decanoylphorbol-13-acetate-promoted Epstein-Barr virus early antigen activation." Pharmacol Res 45(3): 213–220.CrossRefPubMedGoogle Scholar
  73. Katoh, M. (2002). "Expression of human SOX7 in normal tissues and tumors." Int J Mol Med 9(4): 363–368.PubMedGoogle Scholar
  74. Katoh, M. (2002). "Molecular cloning and characterization of human SOX17." Int J Mol Med 9(2): 153–157.PubMedGoogle Scholar
  75. Keetch, D.W., W.J. Catalona, et al. (1994). "Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values." J Urol 151(6): 1571–1574.PubMedGoogle Scholar
  76. Kirschenbaum, A., X. Liu, et al. (2001). "The role of cyclooxygenase-2 in prostate cancer." Urology 58(2 Suppl 1): 127–131.CrossRefPubMedGoogle Scholar
  77. Klein, E.A., I.M. Thompson, et al. (2000). "SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design." Prostate Cancer Prostatic Dis 3(3): 145–151.CrossRefPubMedGoogle Scholar
  78. Klein, E.A., I.M. Thompson, et al. (2001). "SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial." J Urol 166(4): 1311–1315.CrossRefPubMedGoogle Scholar
  79. Knaus, J. (2002). "Saw palmetto for BPH symptoms." Adv Nurse Pract 10(6): 26–27.Google Scholar
  80. Knol, B.W. and S.T. Egberink-Alink (1989). "Androgens, progestagens and agonistic behaviour: a review." Vet Q 11(2): 94–101.PubMedGoogle Scholar
  81. Kunimi, K., U.S. Bergerheim, et al. (1991). "Allelotyping of human prostatic adenocarcinoma." Genomics 11(3): 530–536.CrossRefPubMedGoogle Scholar
  82. Lee, H.L., K.J. Pienta, et al. (2003). "The effect of bone-associated growth factors and cyto-kines on the growth of prostate cancer cells derived from soft tissue versus bone metastases in vitro." Int J Oncol 22(4): 921–926.PubMedGoogle Scholar
  83. Lee, M.M., S.L. Gomez, et al. (2003). "Soy and isoflavone consumption in relation to prostate cancer risk in China." Cancer Epidemiol Biomarkers Prev 12(7): 665–668.PubMedGoogle Scholar
  84. Lee, S.O., W. Lou, et al. (2003). "Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells." Clin Cancer Res 9(1): 370–376.PubMedGoogle Scholar
  85. Letran, J.L., A.B. Blase, et al. (1998). "Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma." J Urol 160(2): 426–429.CrossRefPubMedGoogle Scholar
  86. Levine, M.A., M. Ittman, et al. (1998). "Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer." J Urol 159(2): 471–475; discussion 475–476.CrossRefPubMedGoogle Scholar
  87. Lim, J.T., G.A. Piazza, et al. (1999). "Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines." Biochem Pharmacol 58(7): 1097–1107.CrossRefPubMedGoogle Scholar
  88. Liu, X.H., A. Kirschenbaum, et al. (2000). "Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo." J Urol 164(3 Pt 1): 820–825.CrossRefPubMedGoogle Scholar
  89. Liu, X.H., S. Yao, et al. (1998). "NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells." Cancer Res 58(19): 4245–4249.PubMedGoogle Scholar
  90. Lokeshwar, B.L. (1999). "MMP inhibition in prostate cancer." Ann NY Acad Sci 878: 271–289.PubMedGoogle Scholar
  91. Lui, P.D., M.K. Terris, et al. (1995). "Indications for ultrasound guided transition zone biopsies in the detection of prostate cancer." J Urol 153(3 Pt 2): 1000–1003.CrossRefPubMedGoogle Scholar
  92. Maliner-Stratton, M.S., R.D. Klein, et al. (2001). "Interleukin-1 beta-induced promatrilysin expression is mediated by NFkappaB-regulated synthesis of interleukin-6 in the prostate carcinoma cell line, LNCaP." Neoplasia 3(6): 509–520.CrossRefPubMedGoogle Scholar
  93. Marshall, J.R. (2001). "High-grade prostatic intraepithelial neoplasia as an exposure biomarker for prostate cancer chemoprevention research." IARC Sci Publ 154: 191–198.PubMedGoogle Scholar
  94. Mason, M.D., G. Davies, et al. (2002). "Cell adhesion molecules and adhesion abnormalities in prostate cancer." Crit Rev Oncol Hematol 41(1): 11–28.PubMedGoogle Scholar
  95. McDonnell, T.J., P. Troncoso, et al. (1992). "Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer." Cancer Res 52(24): 6940–6944.PubMedGoogle Scholar
  96. Mercurio, F. and A.M. Manning (1999). "NF-kappaB as a primary regulator of the stress response." Oncogene 18(45): 6163–6171.CrossRefPubMedGoogle Scholar
  97. Merseburger, A.S., M.A. Kuczyk, et al. (2003). "Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues." Oncol Rep 10(1): 223–228.PubMedGoogle Scholar
  98. Miller, E.A., J.L. Stanford, et al. (2001). "Polymorphic repeats in the androgen receptor gene in high-risk sibships." Prostate 48(3): 200–205.CrossRefPubMedGoogle Scholar
  99. Miltyk, W., C.N. Craciunescu, et al. (2003). "Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer." Am J Clin Nutr 77(4): 875–882.PubMedGoogle Scholar
  100. Mitchell, S.H., W. Zhu, et al. (1999). "Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells." Cancer Res 59(23): 5892–5895.PubMedGoogle Scholar
  101. Mononen, N., K. Syrjakoski, et al. (2000). "Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene." Cancer Res 60(22): 6479–6481.PubMedGoogle Scholar
  102. Moody, T.W., J. Leyton, et al. (1998). "Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth." Exp Lung Res 24(4): 617–628.PubMedGoogle Scholar
  103. Mori, S., K. Murakami-Mori, et al. (1999). "Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor." Anticancer Res 19(2A): 1011–1015.PubMedGoogle Scholar
  104. Mundy, G.R. (1997). "Mechanisms of bone metastasis." Cancer 80(8 Suppl): 1546–1556.CrossRefPubMedGoogle Scholar
  105. Nakagawa, H., Y. Kiyozuka, et al. (2001). "Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator." J Cancer Res Clin Oncol 127(4): 258–264.CrossRefPubMedGoogle Scholar
  106. Narla, G., K.E. Heath, et al. (2001). "KLF6, a candidate tumor suppressor gene mutated in prostate cancer." Science 294(5551): 2563–2566.CrossRefPubMedGoogle Scholar
  107. NCI (2004). PDQ® Clinical Trials Database, National Cancer Institute., Accessed Feb 8, 2005.Google Scholar
  108. NCI (2004). SEER Database., Accessed Feb 8, 2005.Google Scholar
  109. Nelson, M.A., M. Reid, et al. (2002). "Prostate cancer and selenium." Urol Clin North Am 29(1): 67–70.CrossRefPubMedGoogle Scholar
  110. Niles, R.M., M. McFarland, et al. (2003). "Resveratrol is a potent inducer of apoptosis in human melanoma cells." Cancer Lett 190(2): 157–163.CrossRefPubMedGoogle Scholar
  111. Oleksowicz, L. and J.P. Dutcher (1994). "A Review of the New Cytokines: IL-4, IL-6, IL-11, and IL-12." Am J Ther 1(2): 107–115.PubMedGoogle Scholar
  112. O'Shaughnessy, C., E. Prosser, et al. (1996). "Differential stimulation of IL-6 secretion following apical and basolateral presentation of IL-1 on epithelial cell lines." Biochem Soc Trans 24(1): 83S.Google Scholar
  113. Oshima, M., J.E. Dinchuk, et al. (1996). "Suppression of intestinal polyposis in Ape delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)." Cell 87(5): 803–809.CrossRefPubMedGoogle Scholar
  114. Oshima, M., H. Sugiyama, et al. (1993). "APC gene messenger RNA: novel isoforms that lack exon 7." Cancer Res 53(23): 5589–5591.PubMedGoogle Scholar
  115. Ostrander, E.A. and J.L. Stanford (2000). "Genetics of prostate cancer: too many loci, too few genes." Am J Hum Genet 67(6): 1367–1375.CrossRefPubMedGoogle Scholar
  116. Overvad, K. (1998). "Selenium and cancer." Bibl Nutr Dieta(54): 141–149.PubMedGoogle Scholar
  117. Panaiotov, D. (1978). "[Testosterone, its biosynthesis, transport and metabolism]." Vutr Boles 17(4): 15–21.Google Scholar
  118. Park, S.J., H. Miyake, et al. (2003). "Predictors of prostate cancer on repeat transrectal ultrasound-guided systematic prostate biopsy." Int J Urol 10(2): 68–71.CrossRefPubMedGoogle Scholar
  119. Perachino, M., L. di Ciolo, et al. (1997). "Results of rebiopsy for suspected prostate cancer in symptomatic men with elevated PSA levels." Eur Urol 32(2): 155–159.PubMedGoogle Scholar
  120. Pollack, A., D. Cowen, et al. (2003). "Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x." Cancer 97(7): 1630–1638.CrossRefPubMedGoogle Scholar
  121. Prasad, S., P. Thraves, et al. (1998). "Cytoskeletal and adhesion protein changes during neoplastic progression of human prostate epithelial cells." Crit Rev Oncol Hematol 27(1): 69–79.PubMedGoogle Scholar
  122. Presti, J.C. (2002). Systemic Biopsy of the Prostate: Applications for Detection, Staging and Risk Assessment. Prostate Cancer Principles and Practice, Lippencott Williams & Wilkins, 16:225–231.Google Scholar
  123. Pruthi, R.S., J.E. Derksen, et al. (2004). "A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy." BJU Int 93(3): 275–278.CrossRefPubMedGoogle Scholar
  124. Qian, J., R.B. Jenkins, et al. (1997). "Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization." Mod Pathol 10(11): 1113–1119.PubMedGoogle Scholar
  125. Quinn, M. and P. Babb (2002). "Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries." BJU Int 90(2): 174–184.CrossRefPubMedGoogle Scholar
  126. Raap, T., H.P. Justen, et al. (2000). "Neurotransmitter modulation of interleukin 6 (IL-6) and IL-8 secretion of synovial fibroblasts in patients with rheumatoid arthritis compared to osteoarthritis." J Rheumatol 27(11): 2558–2565.PubMedGoogle Scholar
  127. Raffo, A.J., H. Perlman, et al. (1995). "Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo." Cancer Res 55(19): 4438–4445.PubMedGoogle Scholar
  128. Reddy, B.S. and C.V. Rao (2000). "Colon cancer: a role for cyclooxygenase-2-specific nonsteroidal anti-inflammatory drugs." Drugs Aging 16(5): 329–334.PubMedGoogle Scholar
  129. Reed, J.C., T. Miyashita, et al. (1996). "BCL-2 family proteins: regulators of cell death involved in the pathogencsis of cancer and resistance to therapy." J Cell Biochem 60(1): 23–32.CrossRefPubMedGoogle Scholar
  130. Rietbergen, J.B. and F.H. Schroder (1998). "Screening for prostate cancer — more questions than answers." Acta Oncol 37(6): 515–532.CrossRefPubMedGoogle Scholar
  131. Roehrborn, C.G., A. Gregory, et al. (1996). "Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology." Urology 48(6A Suppl): 23–32.CrossRefPubMedGoogle Scholar
  132. Ross, J.S., C.E. Sheehan, et al. (2002). "Prognostic markers in prostate cancer." Expert Rev Mol Diagn 2(2): 129–142.CrossRefPubMedGoogle Scholar
  133. Rosser, C.J., A.O. Reyes, et al. (2003). "Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma." Int J Radiat Oncol Biol Phys 56(1): 1–6.CrossRefPubMedGoogle Scholar
  134. Rovner, E.S., F.J. Schanne, et al. (1997). "Transurethral biopsy of the prostate for persistently elevated or increasing prostate specific antigen following multiple negative transrectal biopsies." J Urol 158(1): 138–141; discussion 141–142.CrossRefPubMedGoogle Scholar
  135. Royuela, M., M. Ricote, et al. (2004). "Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate." J Pathol 202(1): 41–49.CrossRefPubMedGoogle Scholar
  136. Sakr, W.A., D.J. Grignon, et al. (1996). "Age and racial distribution of prostatic intraepithelial neoplasia." Eur Urol 30(2): 138–144.PubMedGoogle Scholar
  137. Sakr, W.A. and A.W. Partin (2001). "Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia." Urology 57(4 Suppl 1): 115–120.CrossRefGoogle Scholar
  138. Sarma, A.V. and D. Schottenfeld (2002). "Prostate cancer incidence, mortality, and survival trends in the United States: 1981–2001." Semin Urol Oncol 20(1): 3–9.CrossRefPubMedGoogle Scholar
  139. Scarlatti, F., G. Sala, et al. (2003). "Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling." Faseb J 17(15): 2339–2341.PubMedGoogle Scholar
  140. Schaid, D.J. (2004). "The Complex Genetic Epidemiology of Prostate Cancer." Hum Mol Genet.Google Scholar
  141. Schiavi, R.C. and D. White (1976). "Androgens and male sexual function: a review of human studies." J Sex Marital Ther 2(3): 214–228.PubMedGoogle Scholar
  142. Sellers, W.R. and D.E. Fisher (1999). "Apoptosis and cancer drug targeting." J Clin Invest 104(12): 1655–1661.PubMedGoogle Scholar
  143. Shamberger, R.J. and D.V. Frost (1969). "Possible protective effect of selenium against human cancer." Can Med Assoc J 100(14): 682.PubMedGoogle Scholar
  144. Sharifi, R., W.B. Waters, et al. (1981). "Diagnosis of cancer of the prostate." Curr Surg 38(5): 297–299.PubMedGoogle Scholar
  145. Singh, R.P., S. Dhanalakshmi, et al. (2002). "Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels." Cancer Res 62(11): 3063–3069.PubMedGoogle Scholar
  146. Slater, S.J., J.L. Seiz, et al. (2003). "Inhibition of protein kinase C by resveratrol." Biochim BiophysActa 1637(1): 59–69.Google Scholar
  147. Soderquist, B., J. Kallman, et al. (1998). "Secretion of IL-6, IL-8 and G-CSF by human endothelial cells in vitro in response to Staphylococcus aureus and staphylococcal exotoxins." Apmis 106(12): 1157–1164.PubMedGoogle Scholar
  148. Spiotto, M.T. and T.D. Chung (2000). "STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP." Prostate 42(2): 88–98.CrossRefPubMedGoogle Scholar
  149. Spiotto, M.T. and T.D. Chung (2000). "STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells." Prostate 42(3): 186–195.CrossRefPubMedGoogle Scholar
  150. Stephenson, R.A. (2002). "Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database." Urol Clin North Am 29(1): 173–181.CrossRefPubMedGoogle Scholar
  151. Stewart, C.S., B.C. Leibovich, et al. (2001). "Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies." J Urol 166(1): 86–91; discussion 91–92.CrossRefPubMedGoogle Scholar
  152. Stewart, J.R., K.L. Christman, et al. (2000). "Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation." Biochem Pharmacol 60(9): 1355–1359.CrossRefPubMedGoogle Scholar
  153. Stewart, J.R., N.E. Ward, et al. (1999). "Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism." Biochemistry 38(40): 13244–13251.CrossRefPubMedGoogle Scholar
  154. Stratton, M.S. and F.R. Ahmann (2003). Molecular Mechanisms of Selenium and Prostate Cancer Chemoprevention. National Biotechnology in the Feed and Food Industry. P. Lyons. London, Nottingham Press. 1: 31–51.Google Scholar
  155. Stratton, M.S., M.E. Reid, et al. (2003). "Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: study design and baseline characteristics of the ‘Watchful Waiting’ Study." Anticancer Drugs 14(8): 595–600.CrossRefPubMedGoogle Scholar
  156. Stratton, M.S., M.E. Reid, et al. (2003). "Selenium and prevention of prostate cancer in high-risk men: the Negative Biopsy Study." Anticancer Drugs 14(8): 589–594.CrossRefPubMedGoogle Scholar
  157. Subbaramaiah, K., W.J. Chung, et al. (1998). "Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells." J Biol Chem 273(34): 21875–21882.CrossRefPubMedGoogle Scholar
  158. Sun, Y. and L.W. Oberley (1996). "Redox regulation of transcriptional activators." Free Radic Biol Med 21(3): 335–348.CrossRefPubMedGoogle Scholar
  159. Sun, Z. and R. Andersson (2002). "NF-kappaB activation and inhibition: a review." Shock 18(2): 99–106.CrossRefPubMedGoogle Scholar
  160. Surh, Y.J., K.S. Chun, et al. (2001). "Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation." Mutat Res 480–481: 243–268.PubMedGoogle Scholar
  161. Tang, X., Y.J. Sun, et al. (2002). "Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells." Cancer Res 62(17): 4903–4908.PubMedGoogle Scholar
  162. Taylor, J.A., 3rd, K.J. Gancarczyk, et al. (2002). "Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer." Urology 60(5): 841–845.CrossRefPubMedGoogle Scholar
  163. Thompson, I.M., P.J. Goodman, et al. (2003). "The influence of finasteride on the development of prostate cancer." N Engl J Med 349(3): 215–224.CrossRefPubMedGoogle Scholar
  164. Thun, M.J., M.M. Namboodiri, et al. (1993). "Aspirin use and risk of fatal cancer." Cancer Res 53(6): 1322–1327.PubMedGoogle Scholar
  165. Tsujimoto, Y. and C.M. Croce (1986). "Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma." Proc Natl Acad Sci USA 83(14): 5214–5218.PubMedGoogle Scholar
  166. Tyagi, A.K., R.P. Singh, et al. (2002). "Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis." Clin Cancer Res 8(11): 3512–3519.PubMedGoogle Scholar
  167. Ukimura, O., O. Durrani, et al. (1997). "Role of PSA and its indices in determining the need for repeat prostate biopsies." Urology 50(1): 66–72.CrossRefPubMedGoogle Scholar
  168. Veltri, R.W., L.S. Marks, et al. (2002). "Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism." Urology 60(4): 617–622.CrossRefPubMedGoogle Scholar
  169. Vermeulen, A. (1991). "Clinical review 24: Androgens in the aging male." J Clin Endocrinol Metab 73(2): 221–224.PubMedGoogle Scholar
  170. Westin, P. and A. Bergh (1998). "Apoptosis and other mechanisms in androgen ablation treatment and androgen independent progression of prostate cancer: a review." Cancer Detect Prev 22(5): 476–484.PubMedGoogle Scholar
  171. Wilasrusmee, C., S. Kittur, et al. (2002). "Immunostimulatory effect of Silybum Marianum (milk thistle) extract." Med Sci Monit 8(11): BR439–443.PubMedGoogle Scholar
  172. Wilt, T.J., A. Ishani, et al. (1998). "Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review." JAMA 280(18): 1604–1609.CrossRefPubMedGoogle Scholar
  173. Winters, S.J., A. Brufsky, et al. (2001). "Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men." Metabolism 50(10): 1242–1247.CrossRefPubMedGoogle Scholar
  174. Wise, G.J., V.K. Marella, et al. (2000). "Cytokine variations in patients with hormone treated prostate cancer." J Urol 164(3 Pt 1): 722–725.CrossRefPubMedGoogle Scholar
  175. Witkamp, R. and M. Monshouwer (2000). "Signal transduction in inflammatory processes, current and future therapeutic targets: a mini review." Vet Q 22(1): 11–16.PubMedGoogle Scholar
  176. Wolter, F., B. Akoglu, et al. (2001). "Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines." J Nutr 131(8): 2197–2203.PubMedGoogle Scholar
  177. Xie, W., Y.C. Wong, et al. (2000). "Correlation of increased apoptosis and proliferation with development of prostatic intraepithelial neoplasia (PIN) in ventral prostate of the Noble rat." Prostate 44(1): 31–39.CrossRefPubMedGoogle Scholar
  178. Xu, J., J.A. Stolk, et al. (2000). "Identification of differentially expressed genes in human prostate cancer using subtraction and microarray." Cancer Res 60(6): 1677–1682.PubMedGoogle Scholar
  179. Yu, L., Z.J. Sun, et al. (2003). "Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer." World J Gastroenterol 9(10): 2341–2343.PubMedGoogle Scholar
  180. Zellweger, T., C. Ninck, et al. (2003). "Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer." Prostate 55(1): 20–29.CrossRefGoogle Scholar
  181. Zi, X. and R. Agarwal (1999). "Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention." Proc Natl Acad Sci USA 96(13): 7490–7495.CrossRefPubMedGoogle Scholar
  182. Zi, X., J. Zhang, et al. (2000). "Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells." Cancer Res 60(20): 5617–5620.PubMedGoogle Scholar
  183. Zucker, S., M. Hymowitz, et al. (1999). "Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications." Ann NY Acad Sci 878: 212–227.PubMedGoogle Scholar

Copyright information

© Springer Berlin Heidelberg 2005

Authors and Affiliations

  • Suzanne Stratton
    • 1
  • Frederick Ahmann
    • 1
  1. 1.College of MedicineUniversity of ArizonaTucson

Personalised recommendations